Clinical Research Directory
Browse clinical research sites, groups, and studies.
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Sponsor: Danish Lung Cancer Group
Summary
The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment. The aim is to study the efficiency as well as the safety of a new treatment option of heterogeneously hypofractionated radiotherapy for patients with locally advanced NSCLC who are not candidates for standard, high-dose chemoradiotherapy, either due to excessive irradiation of normal tissue (defined as category A patients) or due to fragility of the patient (category B patients).
Official title: HERAN-Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
151
Start Date
2018-11-22
Completion Date
2026-12-30
Last Updated
2023-09-11
Healthy Volunteers
No
Conditions
Interventions
Heterogeneously Hypofractionated Radiotherapy
A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
Locations (1)
Aarhus University Hospital
Aarhus, Denmark